


	Home \| Data & Statistics \| Collaborations \| Work with Us \| Publications \| About \| Links

Abnormal Interpretations by Indication for Examination for 714,984 Diagnostic Mammography Examinations from 1996 - 2005

	Work-Up of Abnormal Screening Examination	Short-Interval Follow-Up	Evaluation of Breast Problem/No lump or Lump Unknown	Evaluation of Breast Problem/Palpable Lump	All Diagnostic Examinations
Abnormal interpretation rate*	14.4%	4.1%	6.4%	13.2%	9.6%
Abnormal interpretations	33,517	6,668	12,882	15,414	68,481
All examinations	232,678	163,155	202,490	116,661	714,984
PPV₁ (abnormal interpretation)^†	26.9%	22.2%	31.2%	44.4%	31.2%
Cancers	9,013	1,482	4,023	6,847	21,365
Abnormal interpretations	33,517	6,668	12,882	15,414	68,481
PPV₂ (biopsy recommended)^‡	26.7%	22.5%	31.6%	44.3%	31.1%
Cancers	8,596	1,440	3,775	6,274	20,085
Abnormal interpretations	32,150	6,396	11,954	14,173	64,673
PPV₃ (biopsy performed)^§	31.3%	28.3%	38.3%	50.9%	36.5%
Cancers	7,762	1,339	3,262	5,332	17,695
Abnormal interpretations	24,762	4,726	8,518	10,473	48,479

Notes: Numbers are frequencies unless otherwise indicated. 23,653 (5.2%) examinations were given an initial BI-RADS assessment of zero. The first non-zero assessment within 180 days was used as the final assessment for analysis. Examinations without a non-zero assessment within 180 days were excluded (N=7,943; 1.7%).

^* Abnormal interpretation rate = the percentage of examinations interpreted as suspicious or highly suggestive of malignancy (BI-RADS category 4 or 5).

^† PPV₁ = the percentage of examinations with an abnormal interpretation that results in a tissue diagnosis of cancer within 1 year.

^‡ PPV₂ = the percentage of examinations with an abnormal interpretation and a recommendation for biopsy or surgical consultation that results in a tissue diagnosis of cancer within 1 year.

^§ PPV₃ = the percentage of known biopsies performed as a result of an abnormal interpretation with a recommendation for biopsy or surgical consultation that results in a tissue diagnosis of cancer within 1 year.

The following source must be cited when reproducing this table: NCI-funded Breast Cancer Surveillance Consortium co-operative agreement (U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040). Downloaded xx/xx/xx from the Breast Cancer Surveillance Consortium Web site - http://breastscreening.cancer.gov/data/benchmarks/diagnostic/table3.html

[Return to Performance Benchmarks for Diagnostic Mammography]

Maintained by the Applied Research Program,
Division of Cancer Control and Population Sciences